ESTRO 2024 - Abstract Book

S1161

Clinical - Haematology

ESTRO 2024

Conclusion:

The reporting of breast dose metrics in lymphoma RT requires standardisation, due to the large variety and inconsistency of metrics reported. Our analysis demonstrated reporting at multiple breast dose metrics provides valuable information of the effect of RT technique on dose, yet significant differences were not seen for some comparisons, likely due to infrequent reporting at multiple dose levels. We found the presence of axillary irradiation significantly affects MBD, so recommend it to be stated when describing the patient cohort, and breast dose metrics should not be reported for mixed patient groups with respect to axillary irradiation. Other qualitative variables, such as arm positioning and position on table, have also been suggested to affect breast dose and should be reported more widely to enable comparison between studies. Greater standardisation of reported breast dose metrics will improve individualised modelling of RIBC risk.

Keywords: lymphoma, radiotherapy, systematic-review

References:

[1] Swerdlow AJ, Cooke R, Bates A. et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: A national cohort study. Journal of Clinical Oncology. 2012;30(22):2745 – 2752. https://doi.org/10.1200/JCO.2011.38.8835 [2] Moskowitz CS, Ronckers CM, Chou JF. et al. Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. Journal of Clinical Oncology. 2021;39(27):3012-3022. [3] Mulder RL, Hudson MM, Bhatia S. et al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the international guideline harmonization group. Journal of Clinical Oncology. 2020;38(35):4194 – 4207. https://doi.org/10.1200/JCO.20.00562

1851

Digital Poster

Radiotherapy for Patients with Localized Extragastric or Antibiotics-Unresponsive MALT lymphoma